39 completed, 3 active not recruiting, 2 recruiting, 2 terminated. 47 Phase 2, 14 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 47 | Completed 39, Active not recruiting 3, Recruiting 2, Terminated 2, Withdrawn 1 |
| Phase 1 | 14 | Completed 13, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Pneumococcal Infections: new trials by email Literature Review of Pneumococcal Infections trials Research Report on Pneumococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M), PCV24 vaccine (dose H), PCV24 vaccine (dose M) - Streptococcus Pneumoniae Infection | Phase 1 / Phase 2 | Recruiting | CanSino Biologics Inc. | 854 | 2026-05-24 | 2026-08-05 |
| Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years Sinovac PCV24, Prevnar® - Pneumococcal Infectious Disease | Phase 2 | Recruiting | Sinovac Life Sciences Co., Ltd. | 420 | 2025-11-25 | 2025-12-24 |
| PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700), 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13) - Pneumococcal Infectious Disease | Phase 2 | Completed | Reinovax Biologics Co., LTD | 480 | 2025-09-11 | 2026-07-27 |
| Clinical Trial of PCV24 in Adults Aged ≥18 Years Sinovac Low-dosage PCV24, Sinovac Middle-dosage PCV24, Sinovac High-dosage PCV24 - Pneumococcal Infectious Disease | Phase 1 / Phase 2 | Completed | Sinovac Life Sciences Co., Ltd. | 385 | 2025-06-18 | 2026-04-21 |
| Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants Formulation B, Formulation C, Formulation D - Pneumococcal Disease, Invasive | Phase 2 | Active not recruiting | Inventprise Inc. | 421 | 2025-01-27 | 2025-09-02 |
| A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31 - Pneumococcal Vaccines | Phase 2 | Active not recruiting | Vaxcyte, Inc. | 900 | 2024-11-25 | 2026-05-15 |
| A Study to Learn About How a New Pneumococcal Vaccine Works in Children PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) - Pneumococcal Disease | Phase 2 | Completed | Pfizer | 225 | 2024-07-30 | 2026-03-11 |
| A Study to Learn About How a New Pneumococcal Vaccine Works in Infants PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15) - Pneumococcal Disease | Phase 2 | Active not recruiting | Pfizer | 605 | 2024-07-25 | 2026-10-19 |
| Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine Reinovax PCV24 formulation 1, Reinovax PCV24 formulation 2, Reinovax PCV24 formulation 3 - Pneumococcal Infectious Disease | Phase 2 | Completed | Reinovax Biologics Co., LTD | 992 | 2024-04-20 | 2026-08-17 |
| A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults Multivalent Pneumococcal Vaccine - Formulation 1, Multivalent Pneumococcal Vaccine - Formulation 2, 20-valent pneumococcal conjugate vaccine (20vPnC) - Pneumococcal Disease | Phase 1 / Phase 2 | Completed | Pfizer | 1710 | 2023-12-20 | 2026-09-25 |
| A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers mPnC candidate, mPnC control - Healthy Participants | Phase 2 | Completed | Pfizer | 105 | 2023-11-08 | 2025-05-08 |
| Extension Safety and Immunogenicity Study of GPNV-001 Gamma-PN3, Pneumovax-23, Prevenar-13 - Pneumococcal Infections | Phase 1 / Phase 2 | Completed | GPN Vaccines | 60 | 2023-07-17 | 2024-12-18 |
| Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24 - Pneumococcal Vaccines | Phase 2 | Completed | Vaxcyte, Inc. | 802 | 2023-03-29 | 2025-09-11 |
| A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants AFX3772, Prevnar 13, Prevnar 20 - Pneumonia, Bacterial, Pneumococcal Infections | Phase 2 | Completed | GlaxoSmithKline | 388 | 2022-06-16 | 2026-10-09 |
| A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001) V116, Pneumovax™23 - Pneumonia, Pneumococcal | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 600 | 2019-12-06 | 2022-09-16 |
| Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients. Prevenar13 (PCV13) and Pneumovax (PPS23), Placebo / Pneumovax (PPS23), Blood sample - Splenectomised Patients | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 39 | 2019-08-27 | 2026-07-01 |
| A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine ASP3772, PCV13, PPSV23 - Pneumonia, Bacterial, Healthy Volunteers | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 630 | 2019-01-24 | 2023-12-21 |
| CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study PCV13 - Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection | Phase 2 / Phase 3 | Completed | University of British Columbia | 248 | 2018-08-23 | 2024-03-04 |
| Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis Daptomycin - Pneumococcal Meningitis | Phase 2 | Completed | Centre Hospitalier Universitaire Dijon | 112 | 2018-06-07 | 2024-10-01 |
| Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants Multivalent, Prevnar 13 - Pneumococcal Infections | Phase 2 | Terminated | Pfizer | 565 | 2018-06-01 | 2021-11-30 |
Showing 20 of 47. Sign in to see all of them.
Pneumonia (6) · Pneumonia, Pneumococcal (5) · HIV Infections (2) · Pneumonia, Bacterial (2) · Streptococcal Infections (2) · Infections (1) · Inflammatory Bowel Diseases (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Meningitis, Pneumococcal (1)
Bacterial Infections (47) · Bacterial Infections and Mycoses (47) · Gram-Positive Bacterial Infections (47) · Infections (46) · Streptococcal Infections (45) · Lung Diseases (10) · Respiratory Tract Diseases (10) · Respiratory Tract Infections (10) · Pneumonia (4) · Pneumonia, Bacterial (4) · Immune System Diseases (3) · Blood-Borne Infections (2) · Communicable Diseases (2) · Genital Diseases (2)
13-valent pneumococcal vaccine (20) · 23-valent pneumococcal capsular polysaccharide vaccine (7) · Pneumococcal Vaccines (7) · Heptavalent Pneumococcal Conjugate Vaccine (6) · Vaccines, Combined (4) · Sodium Chloride (3) · CRM197 (non-toxic variant of diphtheria toxin) (2) · PHiD-CV vaccine (2) · 10-valent pneumococcal conjugate vaccine (1) · Blood Specimen Collection (1) · D-Worm (1) · Daptomycin (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Hepatitis A Vaccines (1) · Pentavac (1)
Merck Sharp & Dohme LLC (8) · Pfizer (8) · Assistance Publique - Hôpitaux de Paris (3) · GlaxoSmithKline (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · PATH (2) · Reinovax Biologics Co., LTD (2) · Sinovac Life Sciences Co., Ltd. (2) · Vaxcyte, Inc. (2) · CIHR Canadian HIV Trials Network (1) · CanSino Biologics Inc. (1) · Centre Hospitalier Universitaire Dijon (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · GPN Vaccines (1) · Genocea Biosciences, Inc. (1)
United States (18) · China (5) · France (4) · Puerto Rico (4) · Canada (3) · Finland (2) · Australia (1) · Bangladesh (1) · Chile (1) · Denmark (1) · Fiji (1) · Israel (1) · Kenya (1) · Philippines (1) · Poland (1)
Adriana Weinberg, MD (1) · Amar Safdar, MD (1) · Benjamin Rossi, MD (1) · Ed Clarke, MD PhD (1) · Fiona M Russell, FRACP (1) · Lisa A Jackson, MD, MPH (1) · M C Steinhoff, MD (1)
PMID 30689507, PMID 15882530, PMID 17391816, PMID 18470901, PMID 18799552, PMID 20199764, PMID 20206670, PMID 20435707, PMID 20943882, PMID 21044669, PMID 21539882, PMID 22353593, PMID 23300160, PMID 23535358, PMID 23967126, PMID 29279281, PMID 29559167, PMID 30244873, PMID 30427749, PMID 30648919, PMID 31843266, PMID 32639460, PMID 32716500, PMID 33661716, PMID 33767093, PMID 34525007, PMID 35690500, PMID 36116461, PMID 37491088, PMID 37927075, PMID 38360475, PMID 39883948
2023 (2), 2014 (1), 2016 (1), 2018 (1), 2025 (1)